Matteo Rocco Pastore

Request an appointment

Specialty:

General Internal Medicine Diabetes Endocrinology Adult Endocrinology

Profession:

Diabetologist

Location:

Department of General Medicine, Diabetes, Endocrinology @ Ospedale San Raffaele

Languages:

Request an appointment

Biography

Dr Matteo Rocco Pastore is responsible for the Department of Simple General Medicine dealing with Diabetes, Endocrinology and Metabolic Diseases in the Operational Division of General Medicine for Diabetes and Endocrine Metabolism at the IRCCS Ospedale San Raffaele under the supervision of Professor Emanuele Bosi.

After graduating from the University of Milan in 1986 with a degree in Medicine and Surgery, he specialized in Diabetology in 1989 and Endocrinology in 2004, respectively, at the same university and the Vita Salute San Raffaele University.

With regard to clinical activities, Dr. Pastore works as a therapist in the Department of General Medicine with diabetic and endocrine-metabolic direction and provides specialist consultations in various departments of the hospital. He also carries out outpatient clinical activities in the field of diabetology, paying special attention to the treatment of type 1 diabetes.

He conducts research activities in the field of prediction and prevention of type 1 diabetes and its complications as co-leader of the international research protocol TrialNet.

He is the author and co-author of more than 50 publications in industry scientific journals and book chapters. His Hirsch Index is 11 (WoS). Constantly takes part in national and international industry congresses.

Education

University of Milan
Degree of Doctor of Medicine and Surgery - 1986

University of Milan
Specialization in Diabetology - 1989

Vita Salute San Raffaele University
Vita Salute San Raffaele University - 2004

Do you need an appointment?

Request an appointment

Publications

Latest publications

Endothelial progenitor cells carrying monocyte markers are selectively abnormal in type 1 diabetic patients with early retinopathy

https://www.ncbi.nlm.nih.gov/pubmed/22338095

Gianpaolo Zerbini, Anna Maestroni, Alessio Palini, Gemma Tremolada, Rosangela Lattanzio, Silvia Maestroni, Matteo Rocco Pastore, Antonio Secchi, Riccardo Bonfanti, Chiara Gerhardinger, Mara Lorenzi

Progression to type 1 diabetes in islet cell antibody-positive relatives in the European Nicotinamide Diabetes Intervention Trial: the role of additional immune, genetic and metabolic markers of risk

Diabetologia. May; 49(5):881-90, 2006

P. J. Bingley . E. A. M. Gale . The European Nicotinamide Diabetes Intervention Trial (ENDIT) Group

Increased clonogenic potential of circulating endothelial progenitor cells in patients with type 1 diabetes and proliferative retinopathy

Diabetologia. May;49(5):1109-11, 2006.

Asnaghi V, Lattanzio R, Mazzolari G, Pastore MR, Ramoni A, Maestroni A, Ruggeri D, Luzi L, Brancato R, Zerbini G

Progression to type 1 diabetes in islet cell antibody-positive relatives in the European Nicotinamide Diabetes Intervention Trial: the role of additional immune, genetic and metabolic markers of risk

Diabetologia, May;49(5):881-90, 2006.

P. J. Bingley . E. A. M. Gale . The European Nicotinamide Diabetes Intervention Trial (ENDIT) Group

Lactulose and mannitol intestinal permeability detected by capillary electrophoresis

J Chromatogr B Analyt Technol Biomed Life Sci. Apr 13;834(1-2):183-7, 2006

Paroni R, Fermo I, Molteni L, Folini L, Pastore MR, Mosca A, Bosi E.

European Nicotinamide Diabetes Intervention Trial (ENDIT): a randomised controlled trial of intervention before the onset of type 1 diabetes

Lancet 363(9413):925-34, 2004

Gale EA, Bingley PJ, Emmett CL, Collier T; European Nicotinamide Diabetes Intervention Trial (ENDIT) Group.

Six months of gluten-free diet do not change islet autoantibodies, but improve insulin secretion in subjects at high risk for type 1 diabetes

J Clin Endocrinol Metab 88: 162-165, 2003.

Pastore MR, Bazzigaluppi E, Belloni C, Arcovio C, Bonifacio E, Bosi E.

Update on Worldwide Efforts to Prevent Type 1 Diabetes

Ann N Y Acad Sci 2008;1150:190-196. PMID 19120293, NIHMS225042

Skyler JS and the Type 1 Diabetes TrialNet Study Group

Mixed-Meal Tolerance Test Versus Glucagon Stimulation Test for the Assessment of β-Cell Function in Therapeutic Trials in Type 1 Diabetes

Diabetes Care 2008;31:1966-1971. PMID 18628574, PMC2251636

Greenbaum CJ, Mandrup-Poulsen T, Friedenberg-McGee P, Battelino T, Haastert B, Ludvigsson J, Pozzilli P, Lachin JM, Kolb H, and The Type 1 Diabetes TrialNet Research Group and The European C-peptide Trial Study Group

The TrialNet Natural History Study of the Development of Type 1 Diabetes: objectives, design, and initial results.

Pediatric Diabetes 2009;10:97-104. PMID 18823409

Mahon J, Sosenko JM, Rafkin-Mervis L, Krause-Steinrauf H, Lachin JM, Thompson C, Bingley PJ, Bonifacio E, Palmer JP, Eisenbarth GS, Wolfsdorf J, Skyler JS, for the TrialNet Natural History Committee and Type 1 Diabetes TrialNet Study Group.

The Validation of the Diabetes Prevention Trial-Type 1 Risk Score and the detection of Pre-Diabetes in the TrialNet Natural History Study

Diabetes Care 2011;34:1785-1787. PMID: 21680724,PMC3142063.

Sosenko JM, Skyler JS, Mahon J, Krischer JP, Beam CA, Boulware DC, Greenbaum CJ, Rafkin LE, Cowie C, Cuthbertson D, Palmer JP, the TrialNet and Diabetes Prevention Trial – Type 1 Study Groups

Zinc transporter-8 autoantibodies improve prediction of type 1 diabetes in relatives positive for the standard biochemical autoantibodies

Diabetes Care. 2012 Jun;35(6):1213-8. doi: 10.2337/dc11- 2081. Epub 2012 Mar 23

Yu L, Boulware DC, Beam CA, Hutton JC, Wenzlau JM, Greenbaum CJ, Bingley PJ, Krischer JP, Sosenko JM, Skyler JS, Eisenbarth GS, Mahon JL; Type 1 Diabetes TrialNet Study Group.

The application of the diabetes prevention trial-type 1 risk score for identifying a preclinical state of type 1 diabetes

Diabetes Care. 2012 Jul;35(7):1552-5. doi: 10.2337/dc12-0011. Epub 2012 Apr 30

Sosenko JM, Skyler JS, Mahon J, Krischer JP, Beam CA, Boulware DC, Greenbaum CJ, Rafkin LE, Cowie C, Cuthbertson D, Palmer JP; Type 1 Diabetes TrialNet Study Group; Diabetes Prevention Trial-Type 1 Study Group.

Performance of HbA1c as an early diagnostic indicator of type 1 diabetes in children and youth

Diabetes Care. 2012 Sep;35(9):1821-5. Epub 2012 Jun 14

Vehik K, Cuthbertson D, Boulware D, Beam CA, Rodriguez H, Legault L, Hyytinen M, Rewers MJ, Schatz DA, Krischer JP; TEDDY, TRIGR, Diabetes Prevention Trial–Type 1, and Type 1 Diabetes TrialNet Natural History Study Groups

The prediction of type 1 diabetes by multiple autoantibody levels and their incorporation into an autoantibody risk score in relatives of type 1 diabetic patients

Diabetes Care. 2013 Sep;36(9):2615-20. doi: 10.2337/dc13-0425. Epub 2013 Jul 1

Sosenko JM, Skyler JS, Palmer JP, Krischer JP, Yu L, Mahon J, Beam CA, Boulware DC, Rafkin L, Schatz D, Eisenbarth G; Type 1 Diabetes TrialNet Study Group; Diabetes Prevention Trial-Type 1 Study Group

Use of Dried Capillary Blood Sampling for Islet Autoantibody Screening in Relatives: A Feasibility Study.

Diabetes Technol Ther. 2015 Dec;17(12):867-71. doi: 10.1089/dia.2015.0133. Epub 2015 Sep 16

Bingley PJ, Rafkin LE, Matheson D, Steck AK, Yu L, Henderson C, Beam CA, Boulware DC; TrialNet Study Group.

The relationship between BMI and insulin resistance and progression from single to multiple autoantibody positivity and type 1 diabetes among TrialNet Pathway to Prevention participants

Diabetologia. 2016 Jun;59(6):1186-95. doi: 10.1007/s00125-016-3924-5. Epub 2016 Mar 19

Meah FA, DiMeglio LA, Greenbaum CJ, Blum JS, Sosenko JM, Pugliese A, Geyer S, Xu P, Evans-Molina C; Type 1 Diabetes TrialNet Study Group

Do you need an appointment?

Request an appointment